Objective: To determine the impact of HAART on incidence, regression, and progression of cytopathological abnormalities in HIV-infected women.
Introduction
Cervical cancer was designated as an AIDS-defining illness by the Centers for Disease Control and Prevention in 1993 [1] . Globally, the greatest burden of this disease falls upon women in the developing world, particularly, those in sub-Saharan Africa [2] . Cervical cancer is caused by human papillomaviruses (HPVs) [3] . Among the approximately 40 HPV genotypes that infect the human genital tract, [15] [16] [17] [18] genotypes are considered to be high-risk for causing cervical cancer (HR-HPV) [4] . Coinfection with HIV impacts the natural history of HPV-related cervical disease in several ways. Compared to their HIV-uninfected counterparts, HIV-infected women have an increased prevalence of HPV overall [5] , an increased prevalence of HR-HPV [6] , and a greater likelihood to be concurrently infected with multiple HPV genotypes [5] [6] [7] [8] [9] . Although most HPV infections are transient, HIV-infected women are more likely to have persistent infections [10] , and have a reduced likelihood of regression of HPV-related cervical lesions [11] .
Tremendous progress has been made in the reduction of AIDS-related morbidity and mortality in the last decade and a half due to the use of HAART. HAARTuse has not only decreased the incidence of opportunistic infections among AIDS patient but has also had a positive impact on AIDS-related malignancies such as Kaposi's sarcoma and non-Hodgkin's lymphoma [12] . The impact of HAART therapy on cervical cancer, however, remains uncertain. At the population level, the incidence of cervical cancer has not decreased in the HAART era [12] . Clinical research into the subject has produced conflicting evidence.
South Africa has more people living with HIV than any other nation [13] and has very high rates of cervical cancer [14] . We report the results of a prospective cohort study of HIV-infected South African women comparing risk of progression, regression, and incidence of HPVrelated cervical lesions between those on HAART therapy and those not on HAART therapy.
Methods

Study population
In 2003, a cohort of HIV-infected adults from Soweto, South Africa was established to provide pre-HAART care that included 6 monthly CD4 cell counts with referral for HAART according to South African guidelines. The cohort ceased enrolling in September 2010 and stopped follow-up shortly thereafter. Study protocols associated with this cohort have been approved by the Human Research Ethics Committee of the University of the Witwatersrand. Additional details of this cohort have been described in a prior article from our group that ascertained progression and regression of cervical dysplasia in the greater cohort, but did not include an in-depth analysis of the specific role of HAART therapy [15] . The subcohort for this analysis consists of 1123 HIVinfected women with two or more cervical cytology results. Women with high-grade squamous intraepithelial lesion (HSIL) or worse on initial cervical smear were excluded from the study and referred for colposcopy. A total of 2958 cervical smears were obtained from this subcohort for our analysis.
Definitions
For the purposes of this analysis progression was defined as a subsequent smear with worsening cervical dysplasia. The spectrum of possible smear results we used progressed in this order: normal, atypical squamous cells of undetermined significance (ASCUS), low-grade SIL, ASCs cannot rule out a high-grade lesion, HSIL, and cancer. Regression was defined as a subsequent improvement in cytological results. For all analyses, smears were considered to be from women on HAART therapy if they had been receiving HAART for at least 180 days prior to the date of smear collection. HAART regimens were variable among study individuals. Women with incident HSIL or worse were censored from the analysis and referred to the colposcopy clinic in the adjacent hospital for definitive treatment.
Laboratory tests
Cervical smears for cytology analysis were analyzed at the National Health Laboratory Service Cytopathology Division in Johannesburg, which is accredited by the South African National Accreditation System. Results are reported in accordance with the Bethesda System [16] . All smears were verified by a second reader in accordance with laboratory protocol.
Statistical analysis
Our goal was to assess the impact of HAART (the main exposure of interest) on the risk of progression or regression of cervical smear results (the primary outcome measure). Women with only one cervical smear test result were excluded from the analysis. Total follow-up for our cohort ranged from 181 to 2513 days with a median follow-up time of 977 days. The interval between cervical smears needed to be at least 180 days to be considered consecutive. Cervical smear results were treated as dyad comparisons: the smear result from the second clinical visit was compared with the baseline value; the third smear result was compared with the second clinical visit, and so on. This approach allowed a single woman to contribute greater than one episode of regression, progression, or no change between smears Three analyses, a survival analysis and two marginal models, with generalized estimating equations for an association between HAART use and cervical smear results are presented. All analyses include bivariate and multivariate results controlling for BMI, number of sexual partners at baseline, number of sexually transmitted infection (STI) symptoms at initial clinic visit, smoking, and the CD4 cell count that was most temporally proximate to the smear. The survival analysis was restricted to the women not on HAART at baseline who had a normal baseline cervical smear result (n ¼ 767) and assessed the risk of progression to any abnormal result. Women started on HAART during the study period were included in the survival analysis after they had been receiving treatment for 180 days. Two marginal models assessing the risk of progression or regression of cervical smear results at any time based on use of HAART were conducted. The first marginal model compared the risk of cervical smear progression to either no change or regression of cervical smear results. The second marginal model compared the risk of cervical smear regression to either no change or progression. We investigated different correlation structures (independent, autoregressive, unstructured, and exchangeable) and found that an exchangeable correlation structure, which assumes no particular pattern in the correlation of observations within an individual, had the best model fit for our data. The model-based standard errors are presented. Although the marginal model is robust to misspecification of the correlation structure, sensitivity analyses with different correlation structures did not affect our results. All of our analyses were conducted using SAS statistical software (SAS Institute Inc., Cary, United States).
Results
The baseline demographic and clinical characteristics of the 1123 women eligible for this analysis are presented in Table 1 . The mean age at baseline was 32.6 (SD 7.3), and mean BMI was 26.8 (SD 6.2). Fifteen percent of the sample reported ever smoking, 18% were experiencing STI symptoms at the initial clinic visit, and three-quarters reported a sexual partner at the initial clinic visit. Sixteen percent had CD4 cell count values less than 200 cells/ml at baseline. At the time of first cervical smear, 2% of women (n ¼ 19) were on HAART therapy. An additional 17% (n ¼ 193) began HAART therapy during the follow-up period. The number of pap smears per woman ranged from two to seven with an average of 2.6. The interval between consecutive smears ranged from 181 to 2343 days with a median time between consecutive smears of 421 days. The median time between first and second smears was 508 days, that between second and third smears was 419 days, and that between third and fourth smears was 389 days.
In the survival analysis (Table 2) , women who had a normal cervical smear at baseline (n ¼ 767) were found to be 38% less likely to have an incident abnormality in their cervical smear results if they were on HAART than if they were not on HAART (confidence interval (CI) 0.44-0.90, P ¼ 0.01] during our follow-up period. For women on HAART, the median survival time to incident abnormality in cervical smear results was 1753 days, compared with 1475 days among those not on HAART ( Fig. 1 ). These bivariate results did not change when individuals with one or more missing covariate values were excluded. After controlling for covariates, the risk of incident abnormal cervical smear results was 38% lower among women on HAART compared with women not on HAART (CI 0.42-0.91, P ¼ 0.01). Irrespective of HAART, the risk of incident cervical smear abnormality was found to be greater among women with lower CD4 cell counts. Women with most proximate CD4 cell counts less than 200 cells/ml had a risk of incident cervical smear abnormality that was nearly twice as high as the risk among women with counts greater than 500 cells/ml (CI 1.15-2.62, P ¼ 0.001). Excluding cases of ASCUS from the analysis did not change our results.
In the first part of our marginal models analysis (Table 3) in which risk of progression of cervical smear results was compared with the risk of no change or regression, we found that the risk of progression was not significantly different based on HAART use. Although women on HAART were 15% less likely to progress in their cervical smear results, these results were not statistically significant (CI 0.62-1.15, P ¼ 0.29). After controlling for BMI, number of sexual partners, number of STI symptoms, time since study enrollment, and most proximate CD4 In contrast, our second marginal model, comparing risk of regression to the risk of no change or progression in cervical smear results, yielded highly significant results ( Table 3 ). The likelihood of having a regression in cervical smear results was significantly greater among women on HAART compared with those not on HAART.
In bivariate analysis, women on HAART were 2.79 times more likely to regress in their cervical smear results than to progress or have no change than women not on HAART (CI 1.97-3.96, P < 0.0001). This finding remained significant in multivariate analysis in which the likelihood of regression in cervical smear results was 2.61 times greater among women on HAART than women not on HAART (CI 1.75-3.89, P < 0.001).
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Discussion
Our results indicate that compared with non-HAART users, HIV-infected women on HAART are more than twice as likely to exhibit regression of cervical lesions. This finding remained significant in multivariate analysis after controlling for CD4 cell count and other covariates. A nonsignificant trend was identified suggesting a modest corresponding decreased risk of cervical disease progression among HAART users. In addition, our survival analysis indicates that HAARTusers with baseline normal cervical smears are significantly less likely to suffer incident abnormalities in subsequent cervical smears. This finding also remained significant after controlling for covariates.
HAART has had a large and unequivocal impact on the incidence of some HIV-related neoplastic diseases. The incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma has decreased significantly in the HAART era [12] . In contrast, a decrease in the incidence of cervical cancer has not been observed during this period.
Chaturvedi et al. [17] linked US cancer registry data to nearly 500 000 people living with AIDS and found no change in the standardized incidence ratio of cervical cancer among those with AIDS and the general population during a period spanning the pre-HAART and HAART eras. Two additional population level studies conducted in Europe yielded similar results [18, 19] . A meta-analysis of over 20 prospective studies including nearly 50 000 HIV-infected individuals from around the world comparing adjusted incidence rates for cervical cancer before and during the HAART era found no significant change [12] . This population-level research has produced consistent results: the incidence of cervical cancer has not decreased during the HAART era. This observation may be in part due to survival bias. As HAART prolongs the lives of HIV-infected women, it also allows more time for HPV disease progression and the opportunity for cervical cancer to develop.
Unlike population level research, clinical research into the impact of HAART on HPV-related cervical disease has yielded varied and often conflicting results. The findings we present here are at odds with some prior research. In 2001, Lillo et al. [20] reported that rates of cervical disease progression between HAART and non-HAART users were comparable among a cohort of Regression of cervical lesions on HAART Adler et al. 1649 Women with HSIL or worse on initial cervical smear were excluded from the study and referred for colposcopy.
163 HIV-infected women followed for a mean period of 15.4 months. This short follow-up period may have diminished the sensitivity of this study to detect changes in cervical smear results. Schuman et al. [21] similarly reported that no beneficial effects of HAART were identified regarding risk of cervical disease progression or likelihood of regression among a large cohort (n ¼ 774) of HIV-infected women followed with twice yearly cervical smears for up to 5.5 years. Finally, in 2009, Paramsothy et al. [22] reported the results of a large cohort study (n ¼ 537) in which HIV-infected women were followed with semiannual cervical smears for approximately 4 years. They found that although HPV clearance was enhanced among HAART users, no increased likelihood of cervical disease regression was identified.
A number of research studies, however, have reported results that are consistent with our findings. In one of the earliest studies of the subject, a decrease in the prevalence of SIL (69-53%) was found among HAART initiators after a median 5 months of treatment [23] . In 2001, Minkoff et al. [24] reported the results of a large cohort study (n ¼ 741). They found that after adjusting for CD4 cell count, women on HAART were significantly (40%) more likely to exhibit regression and less likely (odds ratio 0.68) to exhibit progression of cervical lesions on serial smears. Like ours, this study analyzed consecutive cervical smears from the same individuals as separate pairs, allowing a single study individual to contribute greater than one episode of regression, progression, or no change between smears. In 2002, Heard et al. [25] followed 168 women with baseline cervical disease and monitored for disease regression, comparing those on HAART to those not receiving HAART. They found the risk of regression of disease to be nearly twice as likely among those on HAART, a finding of similar magnitude to that identified in our study. Similarly, an increased incidence of regression of SIL among HAART users was identified by Ahdieh-Grant et al. [26] in a survival analysis reported in 2004. Lastly, regression of SIL was found to be more common among HAART users in a study of 201 HIVinfected women who were followed with serial cervical smears for a period ranging from 1 to 6 years by Del Mistro et al. [27] . Our results add significant weight to the growing body of research supporting the increased likelihood of regression of cervical lesions in HIV-infected women afforded by HAART.
Our cohort included women with baseline normal and abnormal cervical smears. Those with a baseline normal smear were included in a survival analysis comparing risk of incident abnormal cervical smear between HAART and non-HAART users. Our finding that women on HAART are significantly less likely to have an incident abnormal cervical smear compared with those not on HAARTwas similar to that reported by Soncini et al. [28] in 2007. Using a Cox regression model, they found that HAART significantly reduced the risk of developing cervical disease (hazard ration 0.3; P ¼ 0.004). Similarly, in a cohort of 298 HIV-infected women with a baseline normal smear, Heard et al. [29] reported a relative risk of incident SIL of 0.7 for HAART users, although this finding was not statistically significant (CI 0.4-1.2, P ¼ 0.15). Most recently, Minkoff et al. [30] reported the results of a study assessing the impact of HAART adherence and efficacy on HPV infection and SIL in which study individuals served as their own comparison group. Although HAART adherence was found to be associated with decreased HPV prevalence and increased clearance of SILs, no significant decrease in the incidence of SILs was identified when comparing pre-HAART to adherent or effective HAART users.
A number of limitations of our study require consideration. Although 75% of the consecutive cervical smears in our study participants occurred between intervals ranging from 181 to 701 days (median 421 days), a sizeable number occurred after greater intervals. This could result in missing intervening data that could have an impact on our findings. However, a sensitivity analysis excluding the 25% of smears obtained at intervals greater than 701 days did not affect our main findings. Likewise, each cervical smear in our study is not paired with a specific CD4 measurement due to irregular and sometimes prolonged intervals between testing, so we are unable to draw direct connections between an individual's precise level of immunosuppression and temporally related changes in cervical disease nor are we able to specify a precise date of disease progression and a closely corresponding CD4 cell count. However, 90% of our CD4 collections occurred within 180 days of the most proximate cervical smear (mean 103 days prior, median 32 days prior).
Our study defined a cervical smear as coming from a woman on HAART if she had been taking HAART for at least 180 days prior to the date of the smear; however, no assessment of HAART adherence or efficacy was taken into consideration in our data analysis. In this sense, we have handled HAART from an intention-to-treat perspective. Our study was not designed to assess the incremental impact of increasing duration of HAART therapy on HPV-related cervical disease. In order to address the potential influence of survival bias on our results, we conducted a subgroup analysis in which our cohort was divided into three groups based on duration of HAART therapy (0-2, 2-4, and >4 years). No significant difference in the impact of HAART on progression/regression of cervical smears was identified among these subgroups, although we did identify a trend toward greater protective effect of HAART among those with longer duration on HAART (data not shown).
Not all of the women in our study who were clinically eligible for HAART therapy were receiving it. HAART became widely available in South Africa in April 2004.
Since that time access to HAART in South Africa has been increasing. Our cohort reflects this increase, although, sadly, not all women who met criteria to initiate HAART had begun therapy during our follow-up period. In addition to incomplete access to HAART, surprisingly high rates of HAART refusal in this population may also have contributed to incomplete coverage in our cohort [31] .
Our laboratory data are entirely cytopathological. Unlike many of the studies of this subject, no virological data were obtained. As we lack data on HR-HPV DNA from our participants, we are unable to draw any firm conclusions regarding the impact of HAART on HR-HPV prevalence or persistence. Although HR-HPV infection may be impacted by the immune reconstitution afforded by HAART, the literature does not support the notion of a direct effect of HAARTon HPV (a DNA virus) [32, 33] . Likewise, histological confirmations of cervical smear results were not obtained for our study. Finally, our marginal models analyses produced significant results regarding increased regression of cervical lesions among HAARTusers, but not regarding decreased progression. Although these are separate processes, one would expect HAART to influence them both in a similar fashion. A statistically insignificant trend was identified regarding decreased risk of progression among HAART users.
In summary, our study is among the largest evaluations of the impact of HAART on HPV-related cervical disease. We found that women on HAART were more than twice as likely than non-HAART users to demonstrate regression in consecutive cervical smears. In addition, we found that among those women with a baseline normal smear, those on HAART were significantly less likely to develop an abnormality on future smears. The impact of HAARTon cervical disease has implications for screening practices. If it were conclusively found that HAART decreased the risk of cervical cancer among HIV-infected women to that of the general population, then screening practices could possibly be relaxed in this population. Although this conclusion is far from being reached and a lack of uniformity remains in the literature on this subject, our large prospective cohort study adds significant weight to the side of the balance supporting the positive impact of HAARTon the natural history of HPV-related cervical disease in HIV-infected women.
